Generation Bio to Present at 2020 Wedbush PacGrow Healthcare Virtual Conference

Rhea-AI Summary

Generation Bio (Nasdaq: GBIO), a leader in non-viral gene therapy, will present at the 2020 Wedbush PacGrow Healthcare Virtual Conference on August 12, 2020, at 10:20 a.m. ET. The presentation will highlight their innovative platforms, featuring closed-ended DNA (ceDNA) and a cell-targeted lipid nanoparticle delivery system (ctLNP), aimed at providing long-lasting therapies for both rare and prevalent diseases. A live webcast will be accessible on their investor website, with an archive available for 60 days post-event.

CAMBRIDGE, Mass., Aug. 05, 2020 (GLOBE NEWSWIRE) -- Generation Bio Co. (Nasdaq: GBIO), an innovative genetic medicines company creating a new class of non-viral gene therapy, today announced that management will present at the 2020 Wedbush PacGrow Healthcare Virtual Conference on Wednesday, Aug. 12, 2020 at 10:20 a.m. ET.

A live webcast of the company presentation will be available in the investor section of the company's website at www.generationbio.com. The webcast will be archived for 60 days following the presentation.

About Generation Bio
Generation Bio is an innovative genetic medicines company focused on creating a new class of non-viral gene therapy to provide durable, redosable treatments for people living with rare and prevalent diseases. The company’s non-viral platform incorporates a proprietary, high-capacity DNA construct called closed-ended DNA, or ceDNA; a cell-targeted lipid nanoparticle delivery system, or ctLNP; and an established, scalable capsid-free manufacturing process. The platform is designed to enable multi-year durability from a single dose of ceDNA and to allow titration and redosing if needed. The ctLNP is designed to deliver large genetic payloads, including multiple genes, to specific tissues to address a wide range of indications. The company’s efficient, scalable manufacturing process supports Generation Bio’s mission to extend the reach of gene therapy to more people, living with more diseases, in more places around the world.

For more information, please visit www.generationbio.com. 

Contact:

Investors
Chelcie Lister
THRUST Strategic Communications
chelcie@thrustsc.com
910-777-3049

Media
Stephanie Simon
Ten Bridge Communications
stephanie@tenbridgecommunications.com
617-581-9333

FAQ

When will Generation Bio present at the Wedbush PacGrow Healthcare Virtual Conference?

Generation Bio will present on August 12, 2020, at 10:20 a.m. ET.

How can I watch the Generation Bio conference presentation?

The presentation will be available via a live webcast on Generation Bio's investor website, with an archive accessible for 60 days afterward.

What is the focus of Generation Bio's gene therapy approach?

Generation Bio focuses on non-viral gene therapy aimed at providing durable and redosable treatments for various diseases using closed-ended DNA (ceDNA) and a cell-targeted lipid nanoparticle delivery system (ctLNP).

What technology does Generation Bio utilize in its therapies?

Generation Bio utilizes a proprietary high-capacity DNA construct called closed-ended DNA (ceDNA) and a cell-targeted lipid nanoparticle delivery system (ctLNP) for their therapies.

What is the stock symbol for Generation Bio?

The stock symbol for Generation Bio is GBIO.